Nothing Special   »   [go: up one dir, main page]

WO2017095918A3 - Methods for treating cancer using rspo3 antagonists - Google Patents

Methods for treating cancer using rspo3 antagonists Download PDF

Info

Publication number
WO2017095918A3
WO2017095918A3 PCT/US2016/064207 US2016064207W WO2017095918A3 WO 2017095918 A3 WO2017095918 A3 WO 2017095918A3 US 2016064207 W US2016064207 W US 2016064207W WO 2017095918 A3 WO2017095918 A3 WO 2017095918A3
Authority
WO
WIPO (PCT)
Prior art keywords
rspo3
methods
antagonists
treating cancer
antagonist
Prior art date
Application number
PCT/US2016/064207
Other languages
French (fr)
Other versions
WO2017095918A4 (en
WO2017095918A2 (en
Inventor
Ann M. Kapoun
Chun Zhang
Min Wang
Yu-Wang Liu
Gilbert O'YOUNG
Fiore CATTARUZZA
Original Assignee
Oncomed Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncomed Pharmaceuticals, Inc. filed Critical Oncomed Pharmaceuticals, Inc.
Publication of WO2017095918A2 publication Critical patent/WO2017095918A2/en
Publication of WO2017095918A3 publication Critical patent/WO2017095918A3/en
Publication of WO2017095918A4 publication Critical patent/WO2017095918A4/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention provides compositions for identifying tumors likely to respond to treatment with an RSPO3 antagonist (e.g., anti-RSPO3 antibody). Also provided are methods for identifying tumors and/or patients that are likely to be responsive or non-responsive to treatment with an RSPO3 antagonist (e.g., anti-RSPO3 antibody). Methods for treating a patient with cancer are provided, wherein the cancer is predicted to respond to an RSPO3 antagonist (e.g., anti-RSPO3 antibody).
PCT/US2016/064207 2015-12-01 2016-11-30 Methods for treating cancer using rspo3 antagonists WO2017095918A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562261618P 2015-12-01 2015-12-01
US62/261,618 2015-12-01
US201662308577P 2016-03-15 2016-03-15
US62/308,577 2016-03-15

Publications (3)

Publication Number Publication Date
WO2017095918A2 WO2017095918A2 (en) 2017-06-08
WO2017095918A3 true WO2017095918A3 (en) 2017-07-13
WO2017095918A4 WO2017095918A4 (en) 2017-08-31

Family

ID=58797679

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/064207 WO2017095918A2 (en) 2015-12-01 2016-11-30 Methods for treating cancer using rspo3 antagonists

Country Status (1)

Country Link
WO (1) WO2017095918A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110339364B (en) * 2018-04-02 2021-02-12 上海邦耀生物科技有限公司 LGR4/RSPO blockers in combination with anti-immune checkpoint inhibitors for immunotherapy of tumors
KR102531265B1 (en) * 2019-10-24 2023-05-12 가톨릭대학교 산학협력단 Composition for preventing or treating valvular heart diseases comprising RSPO3 inhbitors

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007100357A2 (en) * 2005-10-07 2007-09-07 Nuvelo, Inc. Stem cell factor-like protein scfa1 and uses thereof
US20070244061A1 (en) * 2003-10-10 2007-10-18 Deutsches Krebsforschungszentrum Compositions for Diagnosis and Therapy of Diseases Associated with Aberrant Expression of Futrins (R-Spondisn) and/or Wnt
WO2012178058A1 (en) * 2011-06-22 2012-12-27 Indiana University Research And Technology Corporation Compositions for and methods of detecting, diagnosing and prognosing thymic cancer
WO2013120056A1 (en) * 2012-02-11 2013-08-15 Genentech, Inc. R-spondin translocations and methods using the same
WO2014165232A1 (en) * 2013-03-12 2014-10-09 Curegenix, Inc. Compounds for treatment of cancer
WO2015058132A2 (en) * 2013-10-18 2015-04-23 Genentech, Inc. Anti-rspo antibodies and methods of use

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070244061A1 (en) * 2003-10-10 2007-10-18 Deutsches Krebsforschungszentrum Compositions for Diagnosis and Therapy of Diseases Associated with Aberrant Expression of Futrins (R-Spondisn) and/or Wnt
WO2007100357A2 (en) * 2005-10-07 2007-09-07 Nuvelo, Inc. Stem cell factor-like protein scfa1 and uses thereof
WO2012178058A1 (en) * 2011-06-22 2012-12-27 Indiana University Research And Technology Corporation Compositions for and methods of detecting, diagnosing and prognosing thymic cancer
WO2013120056A1 (en) * 2012-02-11 2013-08-15 Genentech, Inc. R-spondin translocations and methods using the same
WO2014165232A1 (en) * 2013-03-12 2014-10-09 Curegenix, Inc. Compounds for treatment of cancer
WO2015058132A2 (en) * 2013-10-18 2015-04-23 Genentech, Inc. Anti-rspo antibodies and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SESHAGIRI, S ET AL.: "Recurrent R-spondin fusions in colon cancer", NATURE LETTER., vol. 488, no. 7413, 30 August 2012 (2012-08-30), pages 660 - 664, XP055060432 *

Also Published As

Publication number Publication date
WO2017095918A4 (en) 2017-08-31
WO2017095918A2 (en) 2017-06-08

Similar Documents

Publication Publication Date Title
IL264049A (en) Compounds, compositions, and methods for the treatment of disease
WO2016109782A3 (en) Methods and compositions for detecting colorectal neoplasias
MX2020012165A (en) Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer.
MX2017003478A (en) Anti-fgfr2/3 antibodies and methods using same.
WO2014153030A3 (en) Methods of treating cancer and preventing cancer drug resistance
WO2017181079A3 (en) Methods for monitoring and treating cancer
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
MX2017011206A (en) Combination of a pd-1 antagonist and eribulin for treating cancer.
WO2014138364A3 (en) Methods of treating and preventing cancer drug resistance
WO2015164392A8 (en) Novel anti-rnf43 antibodies and methods of use
WO2015171558A3 (en) BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
WO2016066634A3 (en) Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer
EP3212658A4 (en) 2',2'-dihalo nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
WO2017066712A3 (en) Modulators of telomere disease
WO2016057683A3 (en) Novel anti-nodal antibodies and methods of using same
WO2013106747A3 (en) Methods and compositions for the treatment and diagnosis of thyroid cancer
WO2015153948A3 (en) Microtentacle imaging in patient tumor samples
WO2014160987A3 (en) Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
MX2018005987A (en) Heterocyclic compounds for the treatment of disease.
WO2017066796A3 (en) Modulators of telomere disease
MX2020000135A (en) New quinolinone compounds.
EP3297728A4 (en) Methods for diagnosing and assessing treatment for cushing's syndrome
WO2017181163A3 (en) Methods and compositions for detection and diagnosis of breast cancer
WO2015187727A3 (en) Molecular mammography
EA201891528A1 (en) COMPOSITIONS AND METHODS OF DETECTION AND TREATMENT OF GASTRIC CANCER

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16871418

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16871418

Country of ref document: EP

Kind code of ref document: A2